1119 related articles for article (PubMed ID: 18186095)
1. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.
Adams EW; Ratner DM; Seeberger PH; Hacohen N
Chembiochem; 2008 Jan; 9(2):294-303. PubMed ID: 18186095
[TBL] [Abstract][Full Text] [Related]
2. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
3. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
[TBL] [Abstract][Full Text] [Related]
4. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells.
Pooley JL; Heath WR; Shortman K
J Immunol; 2001 May; 166(9):5327-30. PubMed ID: 11313367
[TBL] [Abstract][Full Text] [Related]
5. Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(-/-) mice.
Caminschi I; Vremec D; Ahmet F; Lahoud MH; Villadangos JA; Murphy KM; Heath WR; Shortman K
Mol Immunol; 2012 Feb; 50(1-2):9-17. PubMed ID: 22209163
[TBL] [Abstract][Full Text] [Related]
6. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
[TBL] [Abstract][Full Text] [Related]
7. Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
Chung Y; Chang JH; Kim BS; Lee JM; Kim HY; Kang CY
Eur J Immunol; 2007 Jun; 37(6):1453-62. PubMed ID: 17474148
[TBL] [Abstract][Full Text] [Related]
8. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.
Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S
J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583
[TBL] [Abstract][Full Text] [Related]
9. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.
Schreibelt G; Klinkenberg LJ; Cruz LJ; Tacken PJ; Tel J; Kreutz M; Adema GJ; Brown GD; Figdor CG; de Vries IJ
Blood; 2012 Mar; 119(10):2284-92. PubMed ID: 22234694
[TBL] [Abstract][Full Text] [Related]
10. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination.
Bonifaz LC; Bonnyay DP; Charalambous A; Darguste DI; Fujii S; Soares H; Brimnes MK; Moltedo B; Moran TM; Steinman RM
J Exp Med; 2004 Mar; 199(6):815-24. PubMed ID: 15024047
[TBL] [Abstract][Full Text] [Related]
11. Toll-Like Receptor 4 Triggering Promotes Cytosolic Routing of DC-SIGN-Targeted Antigens for Presentation on MHC Class I.
Horrevorts SK; Duinkerken S; Bloem K; Secades P; Kalay H; Musters RJ; van Vliet SJ; García-Vallejo JJ; van Kooyk Y
Front Immunol; 2018; 9():1231. PubMed ID: 29963041
[TBL] [Abstract][Full Text] [Related]
12. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
[TBL] [Abstract][Full Text] [Related]
13. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.
Herrera OB; Brett S; Lechler RI
Vaccine; 2002 Dec; 21(3-4):231-42. PubMed ID: 12450698
[TBL] [Abstract][Full Text] [Related]
14. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
15. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
[TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes.
Macri C; Dumont C; Panozza S; Lahoud MH; Caminschi I; Villadangos JA; Johnston AP; Mintern JD
Mol Immunol; 2017 Jan; 81():143-150. PubMed ID: 27978488
[TBL] [Abstract][Full Text] [Related]
17. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
Machy P; Serre K; Baillet M; Leserman L
J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
[TBL] [Abstract][Full Text] [Related]
18. Cutting edge: langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo.
Idoyaga J; Cheong C; Suda K; Suda N; Kim JY; Lee H; Park CG; Steinman RM
J Immunol; 2008 Mar; 180(6):3647-50. PubMed ID: 18322168
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.
Rosalia RA; Quakkelaar ED; Redeker A; Khan S; Camps M; Drijfhout JW; Silva AL; Jiskoot W; van Hall T; van Veelen PA; Janssen G; Franken K; Cruz LJ; Tromp A; Oostendorp J; van der Burg SH; Ossendorp F; Melief CJ
Eur J Immunol; 2013 Oct; 43(10):2554-65. PubMed ID: 23836147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
